 Phenylurea Compounds
"Phenylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the amino-N-phenylamide structure.
| Descriptor ID |
D010671
|
| MeSH Number(s) |
D02.455.426.559.389.703 D02.948.681
|
| Concept/Terms |
Phenylurea Compounds- Phenylurea Compounds
- Compounds, Phenylurea
- Phenylurea Derivatives
- Derivatives, Phenylurea
- Phenylcarbamides
|
Below are MeSH descriptors whose meaning is more general than "Phenylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Phenylurea Compounds".
This graph shows the total number of publications written about "Phenylurea Compounds" by people in this website by year, and whether "Phenylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 4 | 4 | | 2012 | 1 | 2 | 3 | | 2013 | 3 | 3 | 6 | | 2014 | 6 | 2 | 8 | | 2015 | 7 | 1 | 8 | | 2016 | 6 | 4 | 10 | | 2017 | 3 | 2 | 5 | | 2018 | 4 | 1 | 5 | | 2019 | 1 | 0 | 1 | | 2020 | 2 | 3 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 4 | 5 | | 2023 | 0 | 1 | 1 | | 2024 | 3 | 1 | 4 | | 2025 | 2 | 2 | 4 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phenylurea Compounds" by people in Profiles.
-
Wen PY, Berry DA, Buxton MB, Colman H, de Groot J, Lim M, Mellinghoff I, Perry JR, Weller M, Blondin NA, Butt OH, Damek DM, de la Fuente MI, Drappatz J, Dunbar E, Giglio P, Hyddmark EV, Iwamoto F, Jaeckle KA, Kim L, Kling HM, Lee EQ, Mantica M, Mikkelsen T, Nabors B, Newton HB, Olson JJ, Schiff D, Walbert T, Weathers SP, Cloughesy T, Lassman AB. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. J Clin Oncol. 2026 06 20; 44(18):1676-1686.
-
Corr BR, Thomas SM, Haight PJ, Stock E, Floyd J, Borden LE, Tunnage I, Secord AA, Arend R, Jackson AL, Wright JD, Konecny G, Castellano T, Ko E, Podwika S, Backes F, Spinosa D, Mullen M, Washington C, Pothuri B, Smitherman C, Harsono AAH, Khadraoui H, Suzuki Y, Salani R, Powell K, Subbarao S, Gaillard S. Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. Gynecol Oncol. 2025 10; 201:69-75.
-
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatr Blood Cancer. 2025 Jul; 72(7):e31692.
-
Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. Int J Gynecol Cancer. 2025 09; 35(9):101812.
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 03; 194:98-104.
-
French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767.
-
González-Martín A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 07; 186:182-190.
-
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 03; 34(3):347-359.
-
Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. J Immunother Cancer. 2024 01 19; 12(1).
-
Makker V, Aghajanian C, Cohn AL, Romeo M, Bratos R, Brose MS, Messing M, Dutta L, Dutcus CE, Huang J, Schmidt EV, Orlowski R, Taylor MH. A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. J Clin Oncol. 2023 02 10; 41(5):974-979.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|